Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3730077 | 1.00 | CYP2D6 (0.46) | CYP2D6SRCDPP4F2LMNA | |
| SCHEMBL8122334 | 1.00 | CYP2D6 (0.46) | CYP2D6SRCDPP4F2LMNA | |
| Phenylglycine SCHEMBL30559595 | 0.80 | CYP2D6 (0.56) | CYP2D6SRCDPP4F2LMNA | |
| SCHEMBL28363604 | 0.80 | DPP4 (0.50) | CYP2D6SRCDPP4F2LMNA | |
| Phenylglycine SCHEMBL71958 | 0.80 | CYP2D6 (0.56) | CYP2D6SRCDPP4F2LMNA | |
| Phenylglycine SCHEMBL31402004 | 0.80 | CYP2D6 (0.56) | CYP2D6SRCDPP4F2LMNA | |
| Phenylglycine SCHEMBL11576917 | 0.80 | CYP2D6 (0.56) | CYP2D6SRCDPP4F2LMNA | |
| Phenylglycine SCHEMBL159420 | 0.80 | CYP2D6 (0.56) | CYP2D6SRCDPP4F2LMNA | |
| Phenylglycine SCHEMBL157180 | 0.80 | CYP2D6 (0.56) | CYP2D6SRCDPP4F2LMNA | |
| Phenylglycine SCHEMBL27801493 | 0.80 | CYP2D6 (0.56) | CYP2D6SRCDPP4F2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0864570-A1 | Epoxy-azetidinones, preparation and use thereof | PLIVA farmaceutska, kemijska, prehrambena i kozmeticka industrija, dionicko drustvo (HR) | 1998-09-16 | — | — | EP | claimed |
| EP-0005507-A1 | Process for the fragmentation of 3-(2-hydroxyimino-acetylamino)-2-oxo azetidin compounds and compounds obtained thereby | CIBA-GEIGY AG (CH) | 1979-11-28 | — | — | EP | claimed |
| US-4081595-A | REDUCING AGENTS | SHIONOGI & CO., LTD. (JA) | 1978-03-28 | — | — | US | claimed |
| EP-0864570-A1 | Epoxy-azetidinones, preparation and use thereof | PLIVA farmaceutska, kemijska, prehrambena i kozmeticka industrija, dionicko drustvo (HR) | 1998-09-16 | — | — | EP | disclosed |
| US-4399278-A | 7-AMINO-2 OR 3-CEPHEM-4-CARBOXY COMPOUNDS HAVING ANTIBACTERIAL PROPERTIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-08-16 | — | — | US | disclosed |
| EP-0010313-B1 | 3,7-DISUBSTITUTED-2- OR -3-CEPHEM-4-CARBOXYLIC ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-01-26 | — | — | EP | disclosed |
| US-4327093-A | TREATING INFECTIONS DISEASES, ANTIBACTERIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-04-27 | — | — | US | disclosed |
| US-4288364-A | REACTING A 3-/2-HYDROXYIMINOACETYLAMINO/-2-OXOAZETIDINE WITH AN ORGANIC CARBONATE OR ACYL HALIDE | CIBA-GEIGY CORPORATION (US) | 1981-09-08 | — | — | US | disclosed |
| EP-0010313-A1 | 3,7-Disubstituted-2- or -3-cephem-4-carboxylic acid compounds, pharmaceutical compositions containing them and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-30 | — | — | EP | disclosed |
| EP-0005507-A1 | Process for the fragmentation of 3-(2-hydroxyimino-acetylamino)-2-oxo azetidin compounds and compounds obtained thereby | CIBA-GEIGY AG (CH) | 1979-11-28 | — | — | EP | disclosed |
| US-4081595-A | REDUCING AGENTS | SHIONOGI & CO., LTD. (JA) | 1978-03-28 | — | — | US | disclosed |